Psychostimulants have been recommended as first-line therapy for attention-deficit/hyperactivity disorder (ADHD), and safety concerns related to cardiovascular events in psychostimulant users have attracted increasing attention. However, evidence remains limited regarding the cardiovascular risks associated with methylphenidate use in children and adolescents who have heart disease or a family history of cardiovascular conditions. We conducted a self-controlled case series (SCCS) study using…
